Tourlite Capital Management, an investment management firm, released its third quarter 2024 investor letter, a copy of which can be downloaded here. Tourlite Fund, LP Founder Class returned 4.5% for Q3 2024 and 13.8% year-t0-date while the S&P 500 Index returned 5.9% and 9.3%, respectively. In addition, please check the fund’s top five holdings to know its best picks in 2024.
Tourlite Capital Management highlighted stocks like Arbutus Biopharma Corporation (NASDAQ:ABUS), in the third quarter 2024 investor letter. Arbutus Biopharma Corporation (NASDAQ:ABUS) is a biopharmaceutical...
Create a free account, or log in to read the full article
No credit card required.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.